PTPI has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
PTPI has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Petros Pharmaceuticals's quarterly cash and cash equivalents declined from Sep. 2023 ($17.97 Mil) to Dec. 2023 ($13.34 Mil) but then stayed the same from Dec. 2023 ($13.34 Mil) to Mar. 2024 ($11.08 Mil).
Petros Pharmaceuticals's annual cash and cash equivalents declined from Dec. 2021 ($23.85 Mil) to Dec. 2022 ($9.43 Mil) but then increased from Dec. 2022 ($9.43 Mil) to Dec. 2023 ($13.34 Mil).
The historical data trend for Petros Pharmaceuticals's Cash And Cash Equivalents can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Petros Pharmaceuticals Annual Data | |||||||||||
Trend | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | ||||||
Cash And Cash Equivalents | 2.15 | 17.14 | 23.85 | 9.43 | 13.34 |
Petros Pharmaceuticals Quarterly Data | ||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Cash And Cash Equivalents | Get a 7-Day Free Trial | 8.32 | 7.39 | 17.97 | 13.34 | 11.08 |
Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.
Petros Pharmaceuticals (NAS:PTPI) Cash And Cash Equivalents Explanation
A high number means either:
1) The company has competitive advantage generating lots of cash
2) Just sold a business or bonds (not necessarily good)
A low stockpile of cash usually means poor to mediocre economics.
There are 3 ways to create large cash reserve.
1) Sell new bonds or equity to public
2) Sell business or asset
3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)
When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.
Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.
Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.
Be Aware
Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.
Thank you for viewing the detailed overview of Petros Pharmaceuticals's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.
Wayne Remell Walker | director | 1515 MARKET STREET, SUITE 1720, PHILADELPHIA PA 19103 |
Greg Bradley | director | 200 U.S. 9, SUITE 500, MANALAPAN TOWNSHIP NJ 07726 |
John D Shulman | director, 10 percent owner | |
Jcp Iii Sm Aiv, L.p. | 10 percent owner | 5301 WISCONSIN AVE NW, SUITE 570, WASHINGTON DC 20015 |
Juggernaut Partners Iii Gp, L.p. | 10 percent owner | 5301 WISCONSIN AVE NW, SUITE 570, WASHINGTON DC 20015 |
Juggernaut Partners Iii Gp, Ltd. | 10 percent owner | 5301 WISCONSIN AVE NW, SUITE 570, WASHINGTON DC 20015 |
Metp Holdings Llc | 10 percent owner | 5301 WISCONSIN AVE NW, SUITE 570, WASHINGTON DC 20015 |
Joshua Silverman | director | IROQUOIS CAPITAL MANAGEMENT LLC, 205 EAST 42ND ST - 20TH FL., NEW YORK NY 10017 |
Bruce Bernstein | director | 780 THIRD AVENUE, 12TH FLOOR, NEW YORK NY 10017 |
Keith Lavan | officer: Chief Financial Officer | 200 U.S. 9, SUITE 500, MANALAPAN TOWNSHIP NJ 07726 |
Fady Boctor | officer: Pres. & Chief Comm. Officer | 200 U.S. 9, SUITE 500, MANALAPAN TOWNSHIP NJ 07726 |
Andrew Gesek | officer: President, Timm Medical | 200 U.S. 9, SUITE 500, MANALAPAN TOWNSHIP NJ 07726 |
Metuchen Therapeutics, Llc | 10 percent owner | 5301 WISCONSIN AVE NW, SUITE 570, WASHINGTON DC 20015 |
Mitchell Arnold | officer: Prin. Acct. Off/Prin. Fin. Off | 200 ROUTE 9 NORTH, SUITE 500, MANALAPAN NJ 07726 |
From GuruFocus
By ACCESSWIRE • 12-12-2023
By ACCESSWIRE • 12-12-2023
By ACCESSWIRE • 12-12-2023
By GlobeNewswire GlobeNewswire • 04-28-2022
By GuruFocusNews GuruFocusNews • 04-28-2022
By ACCESSWIRE • 09-07-2023
By GuruFocusNews GuruFocusNews • 04-19-2022
By PurpleRose PurpleRose • 07-19-2022
By ACCESSWIRE ACCESSWIRE • 10-21-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.